---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Targeted therapies and clinical trial enrollment"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Targeted therapies and clinical trial enrollment. Topics: Guideline recommendation of clinical trial enrollment for HLA-A∗02:01-negative patients; Guideline statements on referral and access to clinical trials; Clinical trials as an option in metastatic and recurrent intraocular melanoma; MEK inhibitor selumetinib compared with chemotherapy: response, adverse events, and survival; 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/targeted-therapies-and-clinical-trial-enrollment"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Targeted therapies and clinical trial enrollment

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Targeted Therapies and Clinical Trial Enrollment

<a id="topic-2.2.2.1.5-1"></a>

### Guideline recommendation of clinical trial enrollment for HLA-A∗02:01-negative patients

> “For HLA-A∗02:01-negative patients, in the absence of a standard of care and depending on local resources, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.5-2"></a>

### Guideline statements on referral and access to clinical trials

> “Patients should be referred for the recommendation of first-line locoregional or systemic treatment and discussion of UM clinical trials.”
> “Metastatic disease remains an area of high unmet need and requires ambitious research collaborations.”
> “Patients should have access to experimental treatments, including precision diagnostics and medicine and early-phase clinical trials for solid tumours.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.5-3"></a>

### Clinical trials as an option in metastatic and recurrent intraocular melanoma

> “No effective method of systemic treatment has been identified for patients with metastatic ocular melanoma. Clinical trials are an option for these patients.”
> “Eligible patients should consider participation in clinical trials whenever possible.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.2.1.5-4"></a>

### MEK inhibitor selumetinib compared with chemotherapy: response, adverse events, and survival

> “49% of patients treated with selumetinib achieved tumor regression, with 14% achieving an objective radiographic response to therapy.”
> “Treatment-related adverse events were observed in 97% patients treated with selumetinib, with 37% requiring at least one dose reduction.”
> “In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed.”

Source: [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/)

<a id="topic-2.2.2.1.5-5"></a>

### Selumetinib plus dacarbazine versus placebo plus dacarbazine: phase 3 SUMIT trial of 129 participants

> “The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial”
> “patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine.”
> “A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).”
> “In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32).”
> “In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.”

Source: [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/)

<a id="topic-2.2.2.1.5-6"></a>

### Selumetinib with or without paclitaxel: randomized SelPac trial of 77 participants

> “Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.”
> “The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).”
> “ORR was 14% and 4% in the combination and monotherapy arms respectively.”
> “SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.”
> “No improvement in OS was observed, and the modest improvement in PFS is not practice changing.”

Source: [Sacco et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38547774/)

<a id="topic-2.2.2.1.5-7"></a>

### Systematic review of MEK inhibitors in metastatic uveal melanoma

> “The overall response rate was available in five studies and ranged from 0 to 14% with an average of 2.5%.”
> “The median progression-free survival ranged from 3.1 weeks to 16 weeks.”
> “UM is little responsive to MEK inhibition, regardless of the inhibiting agent and combination partner.”
> “Our results do not support the use of MEK inhibitors in UM.”

Source: [Steeb et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30205280/)

<a id="topic-2.2.2.1.5-8"></a>

### Protein kinase C inhibitor AEB071 monotherapy: phase 1 study of 153 participants

> “Patients with metastatic UM (n = 153) were treated with AEB071 in a phase I, single-arm study.”
> “Preliminary clinical activity was observed, with 3% of patients achieving a partial response and 50% with stable disease (median duration 15 weeks).”
> “In conclusion, the protein kinase C inhibitor AEB071 was well tolerated, and modest clinical activity was observed in metastatic UM.”

Source: [Piperno-Neumann et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32029634/)

<a id="topic-2.2.2.1.5-9"></a>

### Sotrastaurin plus the MEK inhibitor binimetinib: phase 1b trial of 38 participants

> “We therefore conducted this phase Ib study of the combination of sotrastaurin and binimetinib in patients with metastatic uveal melanoma”
> “Thirty-eight patients were treated across six dose levels.”
> “No patient achieved a radiographic response per RECIST v1.1.”
> “Stable disease was observed in 60.5% of patients treated.”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10288853/)

<a id="topic-2.2.2.1.5-10"></a>

### Sotrastaurin plus the PI3K-alpha inhibitor alpelisib: phase 1b study

> “we conducted a phase Ib study to assess the safety of combined sotrastaurin, a PKC inhibitor, and alpelisib, a PI3K inhibitor.”
> “Patients with metastatic uveal melanoma (n = 24) or GNAQ/11 mutant cutaneous melanoma (n = 1) were enrolled on escalating dose levels of sotrastaurin (100–400 mg BID) and alpelisib (200–350 mg QD).”
> “Treatment-related adverse events (AE) occurred in 86% (any grade) and 29% (Grade 3).”
> “No objective responses were observed, and median progression-free survival was 8 weeks (range, 3–51 weeks).”

Source: [Shoushtari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8583628/)

<a id="topic-2.2.2.1.5-11"></a>

### Kinase inhibitors compared with chemotherapy across published studies

> “Immunotherapy with ipilimumab, antiangiogenetic approaches, and kinase inhibitors have not yet proven to be superior to chemotherapy.”

Source: [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
